Otsuka closes Astex acquisition despite last minute detractor
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical has completed its acquisition of the cancer and CNS focused US firm Astex Pharmaceuticals following a successful tender offer, in a transaction valued at around $886m.